Across Britain, a quiet but consequential shift is underway: the promise of restored vitality is being sold at speed, while the slower, harder work of diagnosis and long-term care is being left to the public system. The private testosterone market, projected to nearly double by 2032, has grown faster than the safeguards meant to govern it — raising a question as old as medicine itself: who bears responsibility when commerce and care are not the same thing? Experts writing in The BMJ are asking not whether testosterone therapy has value, but whether the conditions under which it is being prescr
Private testosterone prescribing boom risks patient harm, NHS burden, experts warn
The NHS absorbs the workload without any formal agreement.
Mark
So the worry is that private clinics are prescribing testosterone too loosely?
Mimi
Not just loosely—they're operating under a different standard entirely. The NHS requires repeated testing and careful assessment. Private clinics can move much faster, and they're incentivized to do so. They make money from subscriptions, not from getting the diagnosis right.
Luke
But do we actually know how many people are being treated privately? The article says private prescriptions aren't tracked nationally.
Mimi
That's exactly the problem. We can see the market is growing—£100 to £375 a month, heavy social media marketing—but we don't have hard numbers on how many patients or what their actual diagnoses were.
Mark
What happens when someone starts testosterone privately and then goes to their GP?
Mimi
Officially, the private clinician is responsible. But in practice, patients come to their GP for blood tests or because they're having side effects, and the NHS ends up managing the care without any formal agreement to do so.
Luke
So the NHS is absorbing costs that the private sector created?
Mimi
Exactly. And the longer-term risks—heart problems, kidney issues—those need years of monitoring. A private clinic doesn't have that relationship with the patient.
Mark
Is testosterone actually dangerous, or is this just about who pays for monitoring?
Luke
It's both. Testosterone therapy is legitimate for men with genuine deficiency. But the risk profile changes depending on who's prescribing it and whether anyone's actually watching for complications.
Mimi
The experts aren't saying testosterone is bad. They're saying the diagnostic process matters, and speed-based subscription models can't handle that complexity.
Mark
What would fix this?
Mimi
A national reporting system. Private clinics would have to record why they prescribed, how many patients, what monitoring they did, when care transferred to the NHS. It would create accountability.
Luke
And that would require regulation that doesn't currently exist.
Mimi
Right. Which is why the experts are calling for it now, before the market grows even larger.
O Pulso
- Britain's private testosterone market is racing toward $365 million by 2032, fuelled by online clinics and subscription models that promise fast diagnosis and home delivery — but critics say speed is being mistaken for access.
- The diagnostic bar for testosterone deficiency is high by design: it requires repeated blood tests and careful clinical assessment, yet private providers often apply looser standards, treating men with non-specific symptoms that may simply reflect normal ageing.
- When private patients develop side effects, need dose adjustments, or simply stop paying their subscription, NHS GPs inherit the monitoring burden — without any formal agreement, funding, or medical history to guide them.
- Long-term testosterone use carries real cardiovascular and renal risks that require sustained oversight, yet the subscription model is structurally ill-suited to provide it, leaving patients and the public system exposed.
- Experts are calling for a national reporting framework that would compel private prescribers and pharmacies to log their indications, patient numbers, monitoring practices, and care transfers — making accountability visible and enforceable.
Across Britain, a quiet but consequential shift is underway: the promise of restored vitality is being sold at speed, while the slower, harder work of diagnosis and long-term care is being left to the public system. The private testosterone market, projected to nearly double by 2032, has grown faster than the safeguards meant to govern it — raising a question as old as medicine itself: who bears responsibility when commerce and care are not the same thing? Experts writing in The BMJ are asking not whether testosterone therapy has value, but whether the conditions under which it is being prescribed honour the complexity of the human body and the obligations of the clinician.
Britain's private testosterone market is expanding at a pace that has unsettled medical experts, who fear the commercial drive to treat is outrunning the rigour needed to identify who genuinely needs the drug. Valued at around $205 million in 2024 and projected to reach $365 million by 2032, the sector is being propelled by online clinics, subscription services, and social media marketing offering monthly fees between £100 and £375. NHS community dispensing of testosterone rose 52 percent between 2020 and 2025, yet the full scale of private prescribing remains invisible — these transactions are not tracked nationally.
Writing in The BMJ, Stephen Atkin and Eric Kilpatrick argue that the subscription model is fundamentally misaligned with the medical reality of testosterone deficiency, which requires repeated blood tests, careful clinical assessment, and time. Up to one in five men over 50 report symptoms consistent with low testosterone, but fewer than one in a hundred receive NHS treatment — a gap that reflects the NHS's stricter diagnostic threshold, one that private providers frequently do not match.
The fracture point is the informal handoff. A patient may begin testosterone privately under permissive diagnostic standards, then present to an NHS GP for monitoring, dose adjustment, or management of complications — without any formal care agreement in place. The NHS absorbs the workload without the contractual basis to cover it. Over years, cardiovascular and renal risks can emerge, requiring sustained oversight that subscription clinics are not structured to provide. If a patient stops paying or switches providers, their care history may not follow them, and the NHS inherits both the patient and the obligation.
The authors are clear that testosterone replacement is a legitimate and valuable treatment — but only when diagnosis is rigorous and monitoring is continuous. They also flag the additional concern of off-label prescribing to women for low libido associated with menopause, a use that sits further from established evidence and is rarely scrutinised in rapid-access models.
What they are calling for is a national reporting framework requiring private prescribers and dispensing pharmacies to record their indications, patient numbers, monitoring practices, and care transfers. The goal is not to restrict access, but to ensure that whoever initiates long-term hormone therapy takes responsibility for its consequences — rather than passing that burden silently to the public system and, ultimately, to the patient.
Britain's private testosterone market is expanding at a pace that has alarmed medical experts, who worry the rush to treat is outpacing the rigor required to identify who actually needs the drug. The market was valued at roughly $205 million in 2024 and is expected to nearly double to $365 million by 2032, driven by a proliferation of online clinics, subscription services, and social media marketing that promise quick diagnosis and home delivery for monthly fees between £100 and £375. Meanwhile, NHS data tells a parallel story: community dispensing of testosterone rose 52 percent between 2020 and 2025, and prescriptions for women over 50 increased tenfold between 2015 and 2022. Yet the true scale of private prescribing remains unknown because these transactions are not tracked nationally.
Stephen Atkin and Eric Kilpatrick, writing in The BMJ, argue that the commercial model underlying much private testosterone care is fundamentally misaligned with the medical reality of diagnosis. Testosterone deficiency is not a simple matter to establish. It requires repeated blood tests, careful clinical assessment, and time—the very things that subscription models built for speed and convenience are not designed to provide. The authors note that up to one in five men over 50 report symptoms consistent with low testosterone, yet fewer than one in a hundred receive treatment through the NHS. This gap between symptom prevalence and actual treatment reflects the NHS's stricter diagnostic threshold, which private providers often do not match.
The diagnostic complexity is where the system begins to fracture. Professional societies offer differing guidance on what testosterone level warrants treatment, and private clinics tend toward the more permissive end of that spectrum. A patient can start testosterone privately against one standard, then present to an NHS GP for ongoing monitoring or management of side effects, creating an informal handoff that was never formally agreed. The responsibility for initiating care rests with the private clinician, but in practice the NHS absorbs the workload—blood tests, adjustment of doses, management of complications—without any contractual arrangement to cover it.
The longer-term risks of testosterone therapy compound this problem. Heart and kidney complications can emerge over years of treatment, requiring sustained monitoring that private clinics are not structured to provide. If a patient stops paying their subscription fee or switches providers, their medical history and ongoing care needs may not follow them. The NHS then inherits both the patient and the obligation to monitor for harms that the private sector initiated. Atkin and Kilpatrick emphasize that testosterone replacement remains a legitimate and valuable treatment for men with genuine deficiency, but only when diagnosis is rigorous and monitoring is continuous.
The authors also flag a secondary concern: off-label prescribing of testosterone to women, primarily for low libido associated with menopause. This use sits further from established evidence and raises additional safety questions that are rarely addressed in the rapid-access model.
What the experts are calling for is transparency and accountability. They propose a national reporting framework that would require private prescribers and dispensing pharmacies to record why they prescribed testosterone, how many patients they treated, what monitoring they performed, and when care transferred to the NHS. Such a system would create a clear picture of private prescribing patterns and allow regulators to identify clinics that deviate from evidence-based practice. It would also protect patients by ensuring that whoever starts a patient on long-term hormone therapy takes responsibility for the consequences, rather than passing that burden silently to the public system.
The tension at the heart of this issue is real: testosterone therapy works for the right patients, and access should not be artificially restricted. But access built on marketing non-specific symptoms to men experiencing normal aging, without rigorous diagnosis or long-term accountability, is not access—it is a transfer of risk from the private sector to the public one, and from the clinic to the patient.
Citações Notáveis
Rapid access subscription models built around marketing non-specific symptoms are unsuitable to handle the complexity of the diagnostic process and risk unnecessary lifelong treatment and a resulting NHS monitoring burden.— Stephen Atkin and Eric Kilpatrick, writing in The BMJ
A reporting framework for private prescribers and dispensing pharmacies could capture indications, patient numbers, monitoring, and transfers of care, leading to transparent prescribing and demonstrable adherence to evidence-based care.— Atkin and Kilpatrick
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine